Ironwood Pharmaceuticals vs Xeris Biopharma Holdings
Ironwood Pharmaceuticals and Xeris Biopharma Holdings are similar in size: $296m and $292m of revenue in their latest fiscal years. Xeris Biopharma Holdings grew faster (43.7% against -15.7%). Ironwood Pharmaceuticals kept more of each dollar of sales as profit: a net margin of 8.1% against 0.2%.
| Latest fiscal year | Ironwood PharmaceuticalsIRWD, 2025 | Xeris Biopharma HoldingsXERS, 2025 |
|---|---|---|
| Revenue | $296m | $292m |
| Revenue growth | -15.7% | 43.7% |
| Net income | $24.0m | $554,000 |
| Operating margin | 33.3% | 8.5% |
| Net margin | 8.1% | 0.2% |
| Return on equity | — | — |
| Free cash flow | $127m | $28.6m |
| Cash | $215m | $111m |
| Total debt | $585m | $234m |
| Debt to equity | — | 1706.3% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 100 | 435 |
| Market value | $582m | $1.81bn |
| Price vs our value range | Below our value range | — |
| Moat score | 31 (Weak) | 15 (Weak) |
| Insider trades, 12 months | 0 buys, 18 sales | 0 buys, 33 sales |